The prognostic value of programmed death-ligand 1 (PD-L1) expression in resected colorectal cancer without neoadjuvant therapy - differences between antibody clones and cell types

被引：3

作者：

Nobin, Hampus ^{[1
,2
]}

Garvin, Stina ^{[3
]}

Hagman, Helga ^{[4
]}

Nodin, Bjoern ^{[4
]}

Jirstroem, Karin ^{[4
,5
]}

Brunnstroem, Hans ^{[2
,5
]}

机构：

[1] Kalmar Cty Hosp, Dept Pathol, Kalmar, Region Kalmar, Sweden

[2] Lund Univ, Dept Clin Sci Lund, Div Pathol, Lund, Sweden

[3] Linkoping Univ, Dept Clin Pathol, Dept Biomed & Clin Sci, Linkoping, Sweden

[4] Lund Univ, Dept Clin Sci Lund, Div Oncol & Therapeut Pathol, Lund, Sweden

[5] Skane Univ Hosp, Reg Univ Labs, Dept Genet Pathol & Mol Diagnost, Lund, Sweden

来源：

BMC CANCER | 2024年 / 24卷 / 01期

关键词：

73-10; Immune cells; SP263; Survival; MICROSATELLITE INSTABILITY; TUMOR; PATHWAY;

D O I：

10.1186/s12885-024-12812-7

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BackgroundProgrammed death-ligand 1 (PD-L1) expression on tumor cells is associated with poor prognosis in several malignancies, while partly contradictory and inconclusive results have been presented for colorectal cancer (CRC). This study aimed to evaluate PD-L1 as a prognostic biomarker in CRC by comparing three different antibody clones.MethodsPatients surgically treated for CRC between January 1st, 2007, and December 31st, 2015, in Kalmar County, Sweden, were retrospectively included. Tissue microarrays from 862 primary tumors without neoadjuvant treatment were assessed for immunohistochemical expression of PD-L1 in tumor cells (TC) and immune cells (IC) using clones 73-10, SP263, and 22C3. Cox regression proportional hazard models were used to estimate hazard ratios for overall survival (OS) and disease-free interval (DFI) in univariable and multivariable analyses, with 1% and 5% set as cut-offs for positive expression in TC and IC respectively.ResultsPD-L1 expression in TC was found in 89 (10%) cases for clone 73-10, 76 (9%) for clone SP263, and 38 (4%) for clone 22C3, while the numbers for IC were 317 (37%) cases for clone 73-10, 264 (31%) for clone SP263, and 89 (10%) for clone 22C3. PD-L1 expression in IC was associated with prolonged OS and DFI in univariable analysis for all three clones. The link to prolonged DFI remained in multivariable analysis for 73-10 and SP263, but only for 73-10 regarding OS. PD-L1 expression in TC was not prognostic of OS in any analysis, while it was associated with prolonged DFI for SP263, and a trend was seen for 73-10. The link to prolonged DFI remained for SP263 and was strengthened for 73-10 in multivariable analysis.ConclusionsThe prognostic value of PD-L1 expression in both IC and TC differs between antibody clones, with 73-10 and SP263 being more reliable for prognostic information than 22C3 in resected CRC.

引用

页数：16

共 36 条

[1] The clinicopathological features of programmed death ligand-1 expression in colorectal carcinoma [J].

Al-Jussani, Ghada N. ;

Alsughayer, Anas ;

Yousuf, Mustafa S. ;

Mullahuwash, Yaseen ;

Dabbagh, Tamara ;

Sughayer, Maher A. .

INTERNATIONAL JOURNAL OF BIOLOGICAL MARKERS, 2022, 37 (03) :322-327

[2] Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer [J].

Andre, T. ;

Shiu, K-K ;

Kim, T. W. ;

Jensen, B., V ;

Jensen, L. H. ;

Punt, C. ;

Smith, D. ;

Garcia-Carbonero, R. ;

Benavides, M. ;

Gibbs, P. ;

de la Fouchardiere, C. ;

Rivera, F. ;

Elez, E. ;

Bendell, J. ;

Le, D. T. ;

Yoshino, T. ;

Van Cutsem, E. ;

Yang, P. ;

Farooqui, M. Z. H. ;

Marinello, P. ;

Diaz, L. A., Jr. .

NEW ENGLAND JOURNAL OF MEDICINE, 2020, 383 (23) :2207-2218

[3] Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis [J].

Berntsson, Jonna ;

Eberhard, Jakob ;

Nodin, Bjorn ;

Leandersson, Karin ;

Larsson, Anna H. ;

Jirstrom, Karin .

ONCOIMMUNOLOGY, 2018, 7 (08)

[4] Contribution of the PD-L1/PD-1 pathway to T-cell exhaustion: an update on implications for chronic infections and tumor evasion [J].

Blank, Christian ;

Mackensen, Andreas .

CANCER IMMUNOLOGY IMMUNOTHERAPY, 2007, 56 (05) :739-745

[5] Expression of PD-1 and Its Ligands, PD-L1 and PD-L2, in Smokers and Never Smokers with KRAS-Mutant Lung Cancer [J].

Calles, Antonio ;

Liao, Xiaoyun ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Butaney, Mohit ;

Lydon, Christine ;

Dahlberg, Suzanne E. ;

Hodi, F. Stephen ;

Oxnard, Geoffrey R. ;

Jackman, David M. ;

Jaenne, Pasi A. .

JOURNAL OF THORACIC ONCOLOGY, 2015, 10 (12) :1726-1735

[6] PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer [J].

Cercek, Andrea ;

Lumish, Melissa ;

Sinopoli, Jenna ;

Weiss, Jill ;

Shia, Jinru ;

Lamendola-Essel, Michelle ;

El Dika, Imane H. ;

Segal, Neil ;

Shcherba, Marina ;

Sugarman, Ryan ;

Stadler, Zsofia ;

Yaeger, Rona ;

Smith, J. Joshua ;

Rousseau, Benoit ;

Argiles, Guillem ;

Patel, Miteshkumar ;

Desai, Avni ;

Saltz, Leonard B. ;

Widmar, Maria ;

Iyer, Krishna ;

Zhang, Janie ;

Gianino, Nicole ;

Crane, Christopher ;

Romesser, Paul B. ;

Pappou, Emmanouil P. ;

Paty, Philip ;

Garcia-Aguilar, Julio ;

Gonen, Mithat ;

Gollub, Marc ;

Weiser, Martin R. ;

Schalper, Kurt A. ;

Diaz, Luis A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2022, 386 (25) :2363-2376

[7] Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers [J].

Chalabi, Myriam ;

Fanchi, Lorenzo F. ;

Dijkstra, Krijn K. ;

Van den Berg, Jose G. ;

Aalbers, Arend G. ;

Sikorska, Karolina ;

Lopez-Yurda, Marta ;

Grootscholten, Cecile ;

Beets, Geerard L. ;

Snaebjornsson, Petur ;

Maas, Monique ;

Mertz, Marjolijn ;

Veninga, Vivien ;

Bounova, Gergana ;

Broeks, Annegien ;

Beets-Tan, Regina G. ;

de Wijkerslooth, Thomas R. ;

van Lent, Anja U. ;

Marsman, Hendrik A. ;

Nuijten, Elvira ;

Kok, Niels F. ;

Kuiper, Maria ;

Verbeek, Wieke H. ;

Kok, Marleen ;

Van Leerdam, Monique E. ;

Schumacher, Ton N. ;

Voest, Emile E. ;

Haanen, John B. .

NATURE MEDICINE, 2020, 26 (04) :566-+

[8] Clinical impact of programmed cell death ligand 1 expression in colorectal cancer [J].

Droeser, Raoul A. ;

Hirt, Christian ;

Viehl, Carsten T. ;

Frey, Daniel M. ;

Nebiker, Christian ;

Huber, Xaver ;

Zlobec, Inti ;

Eppenberger-Castori, Serenella ;

Tzankov, Alexander ;

Rosso, Raffaele ;

Zuber, Markus ;

Muraro, Manuele Giuseppe ;

Amicarella, Francesca ;

Cremonesi, Eleonora ;

Heberer, Michael ;

Iezzi, Giandomenica ;

Lugli, Alessandro ;

Terracciano, Luigi ;

Sconocchia, Giuseppe ;

Oertli, Daniel ;

Spagnoli, Giulio C. ;

Tornillo, Luigi .

EUROPEAN JOURNAL OF CANCER, 2013, 49 (09) :2233-2242

[9] Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab [J].

Eckstein, Markus ;

Erben, Philipp ;

Kriegmair, Maximilian C. ;

Worst, Thomas S. ;

Weiss, Cleo-Aron ;

Wirtz, Ralph M. ;

Wach, Sven ;

Stoehr, Robert ;

Sikic, Danijel ;

Geppert, Carol I. ;

Weyerer, Veronika ;

Bertz, Simone ;

Breyer, Johannes ;

Otto, Wolfgang ;

Keck, Bastian ;

Burger, Maximilian ;

Taubert, Helge ;

Weichert, Wilko ;

Wullich, Bernd ;

Bolenz, Christian ;

Hartmann, Arndt ;

Erlmeier, Franziska .

EUROPEAN JOURNAL OF CANCER, 2019, 106 :234-243

[10] Programmed Cell Death Ligand 1 Expression Is an Independent Prognostic Factor in Colorectal Cancer [J].

Enkhbat, Tumenjin ;

Nishi, Masaaki ;

Takasu, Chie ;

Yoshikawa, Kozo ;

Jun, Higashijima ;

Tokunaga, Takuya ;

Kashihara, Hideya ;

Ishikawa, Daichi ;

Shimada, Mitsuo .

ANTICANCER RESEARCH, 2018, 38 (06) :3367-3373

← 1 2 3 4 →